|Title:||Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: A 24-week, randomized, double-blind, placebo-controlled study||Authors:||Chen C.-H.
|Issue Date:||2013||Publisher:||Physicians Postgraduate Press Inc.||Journal Volume:||74||Journal Issue:||5||Start page/Pages:||e424-e430||Source:||Journal of Clinical Psychiatry||Abstract:||
Objective: Many studies have shown that metformin can decrease body weight and improve metabolic abnormalities in patients with schizophrenia. Whether or not the beneficial effects can be sustained after discontinuation of metformin needs to be evaluated. We conducted a 24-week randomized, double-blind, placebo-controlled study to evaluate the effect of metformin on metabolic features in clozapine-treated patients with schizophrenia and followed their body weight after stopping the intervention for at least 24 weeks. Method: The study was conducted between September 2008 and July 2011. We recruited patients with DSM-IV diagnosis of schizophrenia or schizoaffective disorder who had been taking clozapine for more than 3 months, were overweight or obese, or fulfilled at least 1 criteria of metabolic syndrome. Eligible patients were randomized to receive metformin 1,500 mg/d or placebo. We followed metabolic features at baseline and at weeks 2, 4, 8, 16, and 24 and rechecked body weight when the patients stopped the trial after at least 24 weeks. Results: A total of 55 subjects (28 in the metformin and 27 in the placebo group) were enrolled. There were no significant differences in all baseline characteristics between the 2 groups, except that patients in the metformin group had higher fasting plasma glucose levels (P = .03). After the 24-week intervention, body weight (P < .0001), body mass index (P < .0001), fasting plasma glucose (P < .0001), high-density lipoprotein cholesterol (P = .03), insulin level (P = .01), and homeostasis model assessment index (P = .02) had significant changes in the metformin group. At the end of the intervention, 8 patients (28.57%) lost more than 7% of their body weight in the metformin group. Mean body weight returned to baseline after patients stopped the intervention in the metformin group. Conclusions: Metformin can significantly reduce body weight and reverse metabolic abnormalities in clozapine-treated patients with schizophrenia and preexisting metabolic abnormalities. However, the beneficial effects of metformin on body weight disappeared after discontinuing this medication. Trial Registration: ClinicalTrials.gov identifier: NCT01300637. ? Copyright 2013 Physicians Postgraduate Press, Inc.
|ISSN:||0160-6689||DOI:||10.4088/JCP.12m08186||SDG/Keyword:||clozapine; glucose; high density lipoprotein cholesterol; insulin; metformin; placebo; triacylglycerol; abdominal obesity; adjuvant therapy; adult; article; body mass; body weight; controlled study; diarrhea; diastolic blood pressure; double blind procedure; drug dose titration; female; follow up; glucose blood level; human; hypertriglyceridemia; lactic acidosis; major clinical study; male; metabolic disorder; metabolic syndrome X; multicenter study; nausea and vomiting; obesity; Positive and Negative Syndrome Scale; priority journal; randomized controlled trial; schizoaffective psychosis; schizophrenia; side effect; systolic blood pressure; waist circumference; weight gain
|Appears in Collections:||流行病學與預防醫學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.